Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company focused on precision cancer medicines, and its news flow reflects ongoing progress in oncology research, clinical development, and corporate strategy. The company describes itself as dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer, using the genetic principle of synthetic lethality to identify and pursue critical targets in tumors.
News about Tango Therapeutics often highlights updates from its clinical pipeline, including vopimetostat (TNG462), an oral MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers, TNG456, a brain-penetrant PRMT5 inhibitor in development for glioblastoma and malignant glioma, and TNG260, a first-in-class CoREST complex inhibitor being evaluated with pembrolizumab in STK11-mutant solid tumors. Press releases have detailed Phase 1/2 clinical data, trial enrollment status, and regulatory designations such as Orphan Drug Designation for TNG456.
The company also issues news on corporate and financial developments, including leadership transitions, board appointments, equity financings, and at-the-market offering agreements documented in SEC filings. Announcements about participation in major healthcare investment conferences and scientific meetings, such as the J.P. Morgan Healthcare Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting, provide additional context on how Tango Therapeutics communicates its strategy and data to investors and the scientific community.
Investors and followers of TNGX can use this news page to review company-issued press releases on clinical results, pipeline milestones, financing transactions, and governance changes, offering a consolidated view of how Tango Therapeutics is advancing its precision oncology programs based on synthetic lethality and targeted cancer biology.
Medivir announced that its licensee, Tango Therapeutics, has discontinued the clinical development of TNG348, a USP1 inhibitor aimed at treating BRCA1/2-mutant and HRD+ cancers, due to toxicity observed in phase 1/2 trials. The program was initially licensed from Medivir in 2020. Despite this setback, Medivir emphasized it remains focused on its lead program, fostroxacitabine bralpamide (fostrox), targeting primary liver cancer. The company is accelerating activities to initiate a pivotal phase 2b study for fostrox, which has the potential to secure market approval for treating HCC patients who fail current first-line treatments, a market projected to be worth $2.5 billion annually by 2028.
Tango Therapeutics (NASDAQ: TNGX) has discontinued its TNG348 program following Phase 1/2 trial results indicating liver toxicity in patients. The company emphasizes patient safety as the primary reason for halting the development of TNG348, a USP1 inhibitor. This decision will allow Tango Therapeutics to redirect resources toward its PRMT5 and CoREST clinical programs, which remain on track. The company has extended its cash runway into 2027 and plans to provide a comprehensive clinical update on TNG908 and TNG462 in the latter half of the year.
Tango Therapeutics, Inc. (NASDAQ: TNGX) reported strong financial results for Q1 2024 with a cash position of $344 million. The company is progressing its clinical programs, including dose expansion in TNG908 and TNG462 trials, with clinical data expected in 2H 2024. Tango is well-funded through late 2026. The company welcomed Julie Carretero as Chief Human Resources Officer to support growth.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
